Life Sciences Tools and Services
Company Overview of Sarah Cannon Research Institute, LLC
Sarah Cannon Research Institute, LLC, a research organization, conducts clinical research programs in the United States. It conducts community-based clinical trials in oncology, cardiology, gastroenterology, internal medicine, pediatrics, obstetrics and gynecology, dermatology, allergy, and ENT. The company provides research site support services to its pharmaceutical and biotechnology partners, which include project management, data management and safety monitoring, oncology research, clinical monitoring, drug development, site qualification, regulatory, safety, quality assurance, medical writing, scientific analysis, and contracting and budget services, as well as biostatistics and site pa...
3322 West End Avenue
Nashville, TN 37203
Founded in 1993
Key Executives for Sarah Cannon Research Institute, LLC
Senior Director of Development Strategy and Operations
President of SCRI Services
Chief Medical Officer and Executive Director for The Overall Drug Development Initiative
Compensation as of Fiscal Year 2014.
Sarah Cannon Research Institute, LLC Key Developments
OncoGenex Pharmaceuticals, Inc. and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce(TM) Clinical Trial Evaluating Apatorsen
Feb 24 15
OncoGenex Pharmaceuticals, Inc. and Sarah Cannon announced that patient enrollment has been completed in the Spruce(TM) clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non-small cell lung cancer (NSCLC). In the Spruce trial, approximately 155 patients were randomized to receive either apatorsen or placebo in combination with carboplatin and pemetrexed therapy. The primary objective of the trial is progression-free survival (PFS), with additional analyses to evaluate overall survival, tumor response rates, safety, tolerability and the effect of therapy on heat shock protein 27 (Hsp27) levels.
Sarah Cannon Research Institute Announces Executive Changes; Opens Office in Cambridge, MA
Dec 5 13
Sarah Cannon Research Institute (SCRI) announced the acquisition of Clinical Development Group (CDG). CDG President, Ann Cahill, has joined SCRI's executive team in the role of Vice President, Program Development and will report to Chief Medical Officer, Howard A. Burris III, MD. Prior to founding CDG, Ann held several leadership positions in drug development with biopharmaceutical companies including Schering-Plough and Vion Pharmaceuticals. In addition to Cahill, several other experienced members of CDG will join the SCRI Development Innovations business unit. While continuing to focus on existing projects, CDG's team will add value and expertise to current and future SCRI projects.
As a result of this acquisition, SCRI has opened an office in Cambridge, MA to better serve its pharmaceutical and biotechnology partners.
Sarah Cannon Research Institute and AstraZeneca Announce Personalized Medicine Partnership and Enhanced Strategic Clinical Development Collaboration
Jul 1 13
Sarah Cannon Research Institute and AstraZeneca announced a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy. Under the agreement, SCRI will work with AstraZeneca to identify potential patients for clinical trials and help explore biomarkers that predict response to specific treatments. In addition, SCRI's enhanced relationship with AstraZeneca will provide clinical program development leadership, medical expertise and oversight, and operational contract research organization (CRO) trial management for early phase clinical development of multiple oncology compounds.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|